On May 2, 2022 Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, reported that the company will present two posters at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, being held in Washington, DC, on May 16-18, 2022 (Press release, Catamaran Bio, MAY 2, 2022, View Source [SID1234613333]). Catamaran scientists will present data supporting CAR‑NK cell therapy design strategies to neutralize the immunosuppressive effects of the tumor microenvironment, including use of synthetic biology-enabled chimeric switch receptors which convert the inhibitory signal of TGF-β into positive NK cell activation signals.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing our progress in engineering CAR-NK cells to confer them with the functional attributes to enable durable efficacy in solid tumors," said Vipin Suri, PhD, MBA, Chief Scientific Officer of Catamaran Bio. "Our presentations at ASGCT (Free ASGCT Whitepaper) describe approaches to mitigate the effects of TGF-β, a highly immunosuppressive cytokine known to reduce the anti-tumor activity of immune cells. We will show data on the activities of multiple TGF-β based synthetic receptors that confer a range of benefits to CAR-NK cells and enhance anti-tumor activity in high TGF-β environments."
Details of the poster presentations are as follows:
Presentation Title: Engineered allogeneic CAR natural killer cells resist tumor microenvironment immunosuppression by expression of a TGF-βR2 dominant negative receptor
Session Title: Cancer – Immunotherapy, Cancer Vaccines I
Session Date & Time: Monday May 16, 2022, 5:30 p.m. ET
Location: Hall D
Abstract Number: 313
Poster Board Number: M-194
Presentation Title: A synthetic biology approach to address the immunosuppressive tumor microenvironment: Novel TGF-β switch receptors convert inhibitory signals to enhance NK cell activity
Session Title: Cancer – Immunotherapy, Cancer Vaccines I
Session Date & Time: Monday May 16, 2022, 5:30 p.m. ET
Location: Hall D
Abstract Number: 331
Poster Board Number: M-212
The abstracts will be available on the ASGCT (Free ASGCT Whitepaper) conference website.